News

The companies will utilize Dicerna’s proprietary GalXC RNAi technology platform to progress new drug targets toward clinical development and commercialization. In addition, the partners will collaborate to move

The companies will conduct both non-clinical and Phase 1 clinical studies of Pfizer’s investigational therapies, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, currently in Phase 2), a Diacylglycerol

Karo Pharma develops and markets products for pharmacies and also directly to the healthcare sector. The specialty pharma company is said to have a strong presence in the

In addition, there is an ongoing earn-out payment based as a percentage of net sales over a 10-year period. Under the terms of the asset purchase, license and

Brolucizumab met its primary endpoint of non-inferiority versus aflibercept in best corrected visual acuity (BCVA) and exhibited superiority in key retinal outcomes at year one (48 weeks). Secondary

The 52-week, randomized, double-blind, placebo-controlled study investigated the LDL-C lowering efficacy and the safety and tolerability of bempedoic acid 180mg in comparison to placebo. It was carried out

Halozyme CEO and president Dr Helen Torley said: “Since the signing of our collaboration with Bristol-Myers Squibb in September 2017, we have formed multiple joint program teams and

A separate research collaboration to conduct preclinical studies evaluating [fam-] trastuzumab deruxtecan in combination with avelumab, the DDR inhibitor and other investigational compounds in Merck KGaA, Darmstadt, Germany’s

The regulator issued a complete response letter (CRL) over the chemistry, manufacturing and controls (CMC) prior-approval supplement (PAS) for the Eylea pre-filled syringe. Eylea injection is a vascular